PDCD1LG2 and neoplasm: reported that anti-PD-L1 antibodies upregulated PD-L2 expression on macrophages; moreover, they showed that mice with MC38 tumors, treated with anti-PD-L1 and PD-L2 inhibitors, exhibited prolonged survival rates compared to the use of either inhibitor alone, highlighting the profound synergistic effects of the combination therapy and long-term memory of the anti-tumor response (102).